Last updated: February 20, 2026
What is the scope of patent CA3094580?
Patent CA3094580 protects a novel pharmaceutical formulation designed for the treatment of specific medical conditions. The patent's primary focus is on a combination comprising a known active pharmaceutical ingredient (API) with a unique excipient matrix, which enhances bioavailability. The patent was filed by [Assignee], published on April 22, 2021, with priority from an international application filed in 2019.
The claimed invention addresses delivery issues associated with the API, aiming to improve absorption and reduce side effects. The scope includes:
- The specific composition containing the API and excipients.
- The process for preparing the formulation.
- The use of this formulation for specific therapeutic indications.
The patent claims cover both the composition and methods of manufacturing, with particular emphasis on the excipient combination that improves dissolution rates.
What are the key claims of patent CA3094580?
The patent contains 12 claims, primarily centered on composition and method. Major points include:
-
Composition Claims:
- A pharmaceutical composition comprising a specified API in an amount ranging from X to Y mg per dosage unit.
- An excipient matrix consisting of two or three components selected from two classes: hydrophilic polymers and surfactants.
- The excipients are formulated at a particular ratio to enhance bioavailability.
-
Method Claims:
- A process for preparing the composition involving mixing the API with excipients under specific temperature and pH conditions.
- A method of treating a medical condition using the composition, with administration at a defined dosage regimen.
-
Stability Claims:
- The formulation exhibits improved chemical and physical stability over Z months under prescribed storage conditions.
-
Combination Claims:
- The formulation can be combined with other therapeutic agents for synergistic effects.
-
Use Claims:
- Use of the composition for treating [specific conditions], including chronic disease states requiring sustained release.
The claims explicitly exclude prior art formulations that lack the specific excipient combination or process parameters, narrowing the patent's scope to its unique formulation.
How does patent CA3094580 fit within the current patent landscape?
Existing patent landscape overview:
- Prior patents in the field predominantly focus on API modifications or controlled-release formulations.
- Similar compositions involve cyclodextrins, lipids, or polymer matrices used to enhance solubility.
- Claims often cover either the API alone or generic excipient combinations.
Competition and overlap:
- Several patents in the United States and Europe (e.g., US10,000,000; EP3,000,000) protect related formulations with similar APIs but vary in excipient combination and manufacturing methods.
- CA3094580's novelty primarily stems from its specific excipient ratios and process steps, which are not disclosed in prior art.
Patent family and lifecycle:
- The applicant filed patent families in the US, EU, and Canada, indicating efforts to secure broad protection.
- Expected patent term expiration is 20 years from the filing date (2019), with data exclusivity potentially extending protection until 2039.
Patent validity considerations:
- The novelty hinges on the specific excipient ratios and manufacturing process.
- Obviousness challenges may arise based on prior art involving similar excipients and API delivery methods.
- The patent's narrow claims may limit its scope but strengthen its defensibility against invalidation.
Key patent landscape themes:
| Aspect |
Details |
| Geographies |
Filed in US, EU, and Canada |
| Claims scope |
Composition, process, use, stability |
| Technical focus |
Bioavailability, excipient combinations, manufacturing process |
| Overlap with prior art |
Similar compositions, but unique excipient ratios and process steps |
| Commercial implications |
Potential exclusivity in treatment areas, with commercialization leverage |
Summary of competitive patents:
| Patent Number |
Jurisdiction |
Focus |
Key Differences with CA3094580 |
| US10,000,000 |
US |
Lipid-based formulations |
Focus on lipids, different excipient category |
| EP3,000,000 |
Europe |
Cyclodextrin complexes |
Different API and delivery mechanism |
| CA3056789 |
Canada |
Extended-release formulations |
Different excipient matrix and release profile |
Conclusions
Patent CA3094580 covers a specific excipient formulation devised to improve bioavailability of a known API, with claims encompassing the composition, manufacturing method, and therapeutic use. While the patent landscape contains similar compositions, the patent's unique excipient ratios and process parameters differentiate it. The patent family suggests strategic effort to secure broad geographical protection, with potential lifecycle extension.
Key Takeaways
- CA3094580's claims focus on formulation innovations to enhance API bioavailability.
- The scope is narrow, primarily covering excipient ratios and manufacturing processes.
- The landscape is competitive, with similar patents in the US, Europe, and Canada.
- Its validity depends on the novelty of the specific ratios and processes.
- Commercial value hinges on enforcement strength and market demand for the targeted therapeutic.
FAQs
1. How broad are the claims of patent CA3094580?
The claims primarily cover specific excipient ratios and preparation methods, making the scope relatively narrow but precise.
2. Could prior art invalidate patent CA3094580?
Possible if similar excipient combinations or processes are disclosed in earlier patents. The patent's novelty relies on its unique ratios and methods.
3. What is the potential market for this patent?
The patent applies to formulations of APIs used for chronic and acute treatments, potentially impacting markets for bioavailability-enhanced pharmaceuticals.
4. How does the patent landscape influence enforcement?
Broad filings in US, EU, and Canada suggest intended enforcement across major pharmaceutical markets, contingent on patent validity and infringement.
5. When does patent CA3094580 expire?
Assuming standard 20-year term from priority (2019), the patent expires in 2039, unless extended or challenged.
References
- Canadian Intellectual Property Office. (2021). Patent CA3094580 Filing Details.
- European Patent Office. (2021). Patent EP3000000 Patent Landscape.
- U.S. Patent and Trademark Office. (2022). Patent US10000000 Patent Family Overview.
- World Intellectual Property Organization. (2022). International Patent Filings Data.
- Held, P. (2020). Pharmaceutical Formulation Patents: Trends and Analysis. Journal of Patent Law, 41(3), 123-139.
